Skip to main content
SABS logo
SABS
(NASDAQ)
SAB Biotherapeutics, Inc.
$3.88-- (--)
Loading... - Market loading

SAB Biotherapeutics (SABS) Balance Sheet

Assets, liabilities, and shareholders' equity with annual and quarterly data.

SAB Biotherapeutics Balance Sheet Analysis

Assets, liabilities, and stockholders equity in millions USD

Scroll to see more
Balance sheet showing assets, liabilities, and shareholders' equity for SAB Biotherapeutics, Inc. (SABS) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2024FY 2023FY 2022FY 2022FY 2021FY 2020FY 2019
Period EndingDec 2025Mar 2025Dec 2024Dec 2023Mar 2023Dec 2022Dec 2021Dec 2020Dec 2019
Current Assets
Cash and Cash Equivalents10.508.908.9056.5715.0515.0533.2112.616.35
Short-Term Investments86.0911.8611.860.000.000.000.000.000.00
Cash & Short-Term Investments96.5920.7620.7656.5715.0515.0533.2112.616.35
Accounts Receivable0.950.050.050.005.565.568.0120.572.82
Inventory0.000.000.000.000.000.000.000.000.00
Other Current Assets3.512.982.982.341.491.498.971.280.12
Total Current Assets101.0523.7923.7958.9122.1022.1050.1934.469.29
Non-Current Assets
Property, Plant & Equipment (Net)19.4019.9219.9224.6828.3428.3430.9522.088.71
Long-Term Investments46.890.000.000.000.000.000.000.000.00
Other Non-Current Assets5.460.480.220.350.470.470.000.000.00
Total Non-Current Assets71.7620.4020.4025.0328.8128.8130.9522.088.71
Total Assets172.8144.2044.2083.9450.9050.9081.1456.5418.00
Current Liabilities
Accounts Payable3.151.691.690.953.683.684.467.382.17
Short-Term Debt0.950.810.281.051.400.771.801.661.95
Current Portion of Long-Term Debt0.000.000.281.050.000.771.800.540.00
Accrued Liabilities6.580.005.475.230.003.504.781.280.00
Deferred Revenue0.000.000.001.320.000.000.100.100.00
Other Current Liabilities6.585.470.006.659.870.096.341.920.50
Total Current Liabilities10.687.987.9810.8114.9914.9926.4611.064.62
Non-Current Liabilities
Long-Term Debt5.003.863.864.054.530.545.426.475.69
Other Non-Current Liabilities5.646.396.3911.770.320.3210.720.0010.00
Total Non-Current Liabilities10.6310.2510.2515.834.854.8516.146.4715.69
Total Liabilities21.3218.2318.2326.6419.8519.8542.5917.5320.31
Stockholders' Equity
Common Stock0.000.000.000.000.010.000.000.000.00
Retained Earnings-110.90-124.17-124.17-90.06-47.87-47.87-29.13-11.98-32.10
Accumulated Other Comprehensive Income0.19-0.14-0.140.030.000.000.000.000.00
Treasury Stock5.520.005.525.520.005.520.000.000.00
Additional Paid-in Capital267.72150.27155.79152.8678.9284.4567.6750.9929.79
Shares Outstanding47.610.009.299.230.005.044.350.000.00
Total Stockholders' Equity151.4925.9725.9757.3031.0631.0638.5539.01-2.31
Total Liabilities & Equity172.8144.2044.2083.9450.9050.9081.1456.5418.00

Frequently Asked Questions About SAB Biotherapeutics Balance Sheet

What is a balance sheet?

A balance sheet shows a company's financial position at a specific point in time. It lists total assets (what the company owns), total liabilities (what it owes), and stockholders' equity (the difference). The fundamental equation: Assets = Liabilities + Equity.

What is stockholders' equity?

Stockholders' equity represents the net value belonging to shareholders — total assets minus total liabilities. It includes retained earnings, common stock, and additional paid-in capital. Growing equity over time typically indicates a healthy, profitable business.

What is working capital?

Working capital is current assets minus current liabilities. It measures a company's ability to pay short-term obligations with short-term assets. Positive working capital indicates the company can cover its near-term debts; negative may signal liquidity risk.

What is SABS's debt level?

Review SAB Biotherapeutics's total long-term debt and short-term borrowings in the balance sheet table above. Compare debt to equity and total assets to assess leverage and financial risk.

What is book value per share?

Book value per share is total stockholders' equity divided by shares outstanding. It represents the accounting value per share if the company were liquidated. Comparing market price to book value gives the price-to-book (P/B) ratio — a key valuation metric.

These financial metrics are calculated using balance sheet data. Learn how each metric works and screen stocks by them.